Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing real-world study of RECARBRIO in Chinese adults with susceptible gram-negative bacterial infections with limited or no alternative treatment options
CTR20263980Phase 4Active
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of imipenem in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infection (cUTI), pyelonephritis, Intra-abdominal infection (IAI), sponsored by Merck & Co.. Started Oct 2026; status: active.
02
Drugs
imipenem
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)complicated urinary tract infection (cUTI)pyelonephritisIntra-abdominal infection (IAI)
Beyond the preview
Go deeper on CTR20263980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263980.